China Life Science Sector Overview 2022: Wading into Deep Waters: Survive and Thrive

January 30, 2023 | BY

Susan Mok

The Chinese government has been deepening its reform over the past year in order to foster evolving regulatory framework. Deeper reforms coupled with a chilled market means life science companies should prioritize their assets and re-position their business strategies in order to survive and grow stronger.

Share:

 

Summary

  • Innovation-driven regulatory environment and economic downturn in the past year have urged life science companies to be more resilient and flexible to current regulatory and market changes.
  • The Chinese government has cultivated an innovation-driven regulatory environment and provide unprecedented market incentives for orphan drugs and pediatric drugs.
  • The legislative development in 2022 addressed various emerging issues in the industry, including cell and gene therapy regulation, cross-region or cross-border regulation, e-commerce regulation.